Table 1 Significant association of MH30, CT60 and JO31 to autoimmune disease in northern Sweden.
MH30 | Case (%) | Control (%) | OR (95%CI) | P value |
|---|---|---|---|---|
CC | 16 (6.7) | 108 (13.9) | ||
CG | 111 (46.4) | 362 (46.6) | ||
GG | 112 (46.9) | 307 (39.5) | ||
CG vs. CC | 2.07 (1.18–3.65) | 0.01 | ||
GG vs. CC | 2.46 (1.40–4.35) | 0.002 | ||
Multiplicative model | 1.40 (1.12–1.75) | 0.004 | ||
Success rate (%) | 94.5 | 89.9 | ||
CT60 | ||||
AA | 15 (6.4) | 117 (14.4) | ||
AG | 111 (47.2) | 394 (48.5) | ||
GG | 109 (46.4) | 301 (37.1) | ||
AG vs. AA | 2.20 (1.23–3.91) | 0.008 | ||
GG vs. AA | 2.83 (1.58–5.05) | 5 × 10-4 | ||
Multiplicative model | 1.50 (1.19–188) | 5 × 10-4 | ||
Success rate (%) | 92.9 | 93.9 | ||
JO31 | ||||
TT | 18 (7.4) | 131 (15.2) | ||
GT | 116 (47.7) | 414 (48.1) | ||
GG | 109 (44.9) | 316 (36.7) | ||
GT vs. TT | 2.04 (1.20–3.48) | 0.009 | ||
GG vs. TT | 2.51 (1.47–4.30) | 8 × 10-4 | ||
Multiplicative model | 1.44 (1.15–1.79) | 0.001 | ||
Success rate (%) | 96.0 | 99.5 |